Europe's Sleep Crisis Costs Billions as Disorders Surge Across 47 Countries

A large-scale study has examined the impact of sleep disorders across 47 European countries. Researchers analysed the prevalence and economic burden of conditions like insomnia, sleep apnoea, and narcolepsy over the past five years. Their findings highlight both the widespread nature of these disorders and their growing financial strain on healthcare systems and workplaces.

The study focused on five key sleep disorders: obstructive sleep apnoea (OSA), insomnia, restless legs syndrome (RLS), narcolepsy, and REM sleep behaviour disorder (RBD). Results showed that OSA was the most common, affecting an estimated 18% of adults. Insomnia followed with a prevalence of 10%, while RLS was reported in 3% of the population. Narcolepsy and RBD were far rarer, occurring in 0.03% and 0.009% of adults, respectively.

Economic data revealed that sleep disorders impose a heavy financial load. Direct costs—such as medical treatments and hospital visits—made up 48% of the total burden. The remaining 52% came from indirect costs, including lost productivity and workplace absences. Between 2021 and 2025, direct costs in 30 countries with available records rose by 15–20%, largely due to increased healthcare use. Meanwhile, indirect costs jumped by 25–30%, driven by higher rates of missed work and reduced efficiency.

Researchers noted that the broader effects of sleep disorders extend beyond finances. Poor sleep has been linked to declines in brain function, physical health, and overall social well-being. Despite this, the full scale of their epidemiological and economic impact remains understudied.

The study provides a clearer picture of how sleep disorders affect millions across Europe. With rising healthcare expenses and productivity losses, the findings underscore the need for better prevention and treatment strategies. Future research may help reduce both the health and financial burdens tied to these conditions.